Abbott (NYSE: ABT), a global healthcare leader, today announced results from the FreeDM2 randomized controlled trial (RCT) showing that people using FreeStyle Libre continuous glucose monitoring (CGM) ...

The healthcare giant is roughly 22% down from its 52-week high of $139.06 as of writing. However, for investors focused on ...

The study was carried out at 24 clinical sites across the UK and included 303 participants.

PODD's Omnipod 5 momentum and strong growth outlook highlight upside, but macro pressures and rising competition could ...

For years, the conversation around getting older has focused on individuals – retirement, lifestyle, healthcare. But a bigger ...

MiniMed is out to prove it deserves the name, with a new FDA clearance for its smallest insulin pump yet.  | At about half ...

A manufacturing problem in millions of Abbott glucose sensors for diabetes patients has been tied to at least seven deaths ...

Is ABT a good stock to buy? We came across a bullish thesis on Abbott Laboratories on Compounding Dividends’s Substack by TJ ...

Should A1c remain the gold standard for routine monitoring of glucose control in people with diabetes, or is it time to shift ...

Tandem Diabetes Care, Inc.’s TNDM impressive product launches are expected to bolster growth in the upcoming quarters. A strong solvency looks encouraging. However, concerns loom over fierce ...

Diabetes technology innovators gathered last week for the Advanced Technologies and Treatments for Diabetes Conference (ATTD ...